New drug combo aims to shrink enlarged spleens in hard-to-treat blood cancer
NCT ID NCT07424950
First seen Feb 21, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tests whether adding bomedemstat to the standard drug momelotinib can help people with myelofibrosis, a rare bone marrow cancer. It includes 40 adults who either did not improve enough on momelotinib alone or had low blood counts. The main goal is to see if the combination reduces spleen size by at least 35% after 24 weeks. Participants will take both drugs for 12 weeks after an initial 12 weeks on momelotinib alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.